Description: FASN inhibitor 1 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
IC50 & Target: FASN
In Vitro: Human PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid (LTA), a Toll 2 receptor agonist. Stimulation with either LPS or LTA plus DMSO, the solvent for FASN inhibitor 1 (Compound 242A), results in secretion of IL-1 beta. FASN inhibitor 1 treatment of PBMC, which is a mixed population of mononuclear cells including both lymphocytes and monocytes, reduces the level of IL-1 beta resulting from either LPS or LTA stimulation. For monocytes, FASN inhibitor 1 treatment reduces the level of IL-1 beta resulting from LTA stimulation whereas there is only a slight reduction after LPS stimulation.
|Contents||1 vial supplied at requested quantity.|
|Targets||Fatty Acid Synthase (FAS)|